Related Experiment Video

Updated: Feb 23, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy

Rafael Ríos-Tamayo1,2,3,4, Agustín Martín-García5,6, Carolina Alarcón-Payer5

  • 1Monoclonal Gammopathies Unit.

Drug Design, Development and Therapy
|September 2, 2017
PubMed

Insights

Pomalidomide (POM) combined with dexamethasone offers a safe and effective treatment for relapsed and refractory multiple myeloma. POM-based therapies are crucial for improving outcomes in this challenging patient group.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma is a heterogeneous cancer with variable patient survival.
  • Relapsed and refractory disease present significant challenges despite treatment advances.
  • Immunomodulatory drugs are essential in multiple myeloma treatment.

Purpose of the Study:

  • To review the pharmacological and clinical aspects of pomalidomide (POM) in relapsed/refractory multiple myeloma.
  • To highlight the efficacy and safety of POM-based combinations.
  • To discuss POM's role in improving outcomes for difficult-to-treat patients.

Main Methods:

  • Review of current literature on pomalidomide in multiple myeloma.
  • Analysis of clinical trial data for POM and POM-based regimens.
  • Pharmacological considerations of POM, including its use in renal impairment.

Main Results:

  • Pomalidomide (POM) and dexamethasone combination is safe and effective in relapsed/refractory multiple myeloma.
  • This combination shows efficacy even in patients with high-risk cytogenetic features.
  • POM can be administered without dose adjustment for renal failure in most cases.

Conclusions:

  • Pomalidomide is a vital agent for relapsed and refractory multiple myeloma.
  • POM-based triplet therapies are being investigated to further enhance treatment results.
  • Understanding POM's pharmacology and clinical application is key to optimizing patient care.
Keywords:
dexamethasonemultiple myelomapomalidomidetriplet therapy

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.5K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
408